Which has higher valuation & earnings, RGEN or INVA?

Innoviva has lower revenue, but higher earnings than Repligen. Innoviva is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Repligen $738.26M 9.47 $48.89M $0.90 137.72 Innoviva $411.33M 3.84 $271.17M $6.01 3.56

Is RGEN or INVA more profitable?

Innoviva has a net margin of 119.89% compared to Repligen's net margin of 6.73%. Innoviva's return on equity of 33.33% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Repligen 6.73% 4.88% 3.48% Innoviva 119.89% 33.33% 22.67%

Does the media refer more to RGEN or INVA?

In the previous week, Repligen had 1 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for Repligen and 4 mentions for Innoviva. Repligen's average media sentiment score of 0.60 beat Innoviva's score of 0.58 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, INVA or ALKS?

Innoviva has higher earnings, but lower revenue than Alkermes. Innoviva is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.84 $271.17M $6.01 3.56 Alkermes $1.48B 4.76 $241.66M $0.90 46.88

Is INVA or ALKS more profitable?

Innoviva has a net margin of 119.89% compared to Alkermes' net margin of 9.78%. Innoviva's return on equity of 33.33% beat Alkermes' return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 119.89% 33.33% 22.67% Alkermes 9.78% 9.26% 5.66%

Does the media favor INVA or ALKS?

In the previous week, Alkermes had 1 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for Alkermes and 4 mentions for Innoviva. Alkermes' average media sentiment score of 1.29 beat Innoviva's score of 0.58 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, INVA or LGND?

Innoviva has higher revenue and earnings than Ligand Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.84 $271.17M $6.01 3.56 Ligand Pharmaceuticals $268.09M 17.34 $124.45M $7.37 31.47

Does the media favor INVA or LGND?

In the previous week, Ligand Pharmaceuticals had 4 more articles in the media than Innoviva. MarketBeat recorded 8 mentions for Ligand Pharmaceuticals and 4 mentions for Innoviva. Ligand Pharmaceuticals' average media sentiment score of 1.34 beat Innoviva's score of 0.58 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, INVA or CLDX?

Innoviva has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.84 $271.17M $6.01 3.56 Celldex Therapeutics $1.54M 1,601.91 -$258.76M -$4.26 N/A

Does the media prefer INVA or CLDX?

In the previous week, Innoviva had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 4 mentions for Innoviva and 2 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.31 beat Innoviva's score of 0.58 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INVA or BCRX?

In the previous week, Innoviva and Innoviva both had 4 articles in the media. BioCryst Pharmaceuticals' average media sentiment score of 0.91 beat Innoviva's score of 0.58 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Innoviva (INVA) Competitors

$21.42 0.00 (0.00%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$21.41 -0.01 (-0.05%)

As of 05/29/2026 05:40 PM Eastern

Compare

INVA vs. RGEN, ALKS, LGND, CLDX, and BCRX

Should you buy Innoviva stock or one of its competitors? MarketBeat compares Innoviva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Innoviva include Repligen (RGEN), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Celldex Therapeutics (CLDX), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "biotechnology" industry.

How does Innoviva compare to Repligen?

Repligen (NASDAQ:RGEN) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Repligen currently has a consensus target price of $166.15, suggesting a potential upside of 34.05%. Innoviva has a consensus target price of $36.20, suggesting a potential upside of 69.00%. Given Innoviva's higher probable upside, analysts clearly believe Innoviva is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Repligen had 1 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for Repligen and 4 mentions for Innoviva. Repligen's average media sentiment score of 0.60 beat Innoviva's score of 0.58 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a net margin of 119.89% compared to Repligen's net margin of 6.73%. Innoviva's return on equity of 33.33% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	6.73%	4.88%	3.48%
Innoviva	119.89%	33.33%	22.67%

Innoviva has lower revenue, but higher earnings than Repligen. Innoviva is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	9.47	$48.89M	$0.90	137.72
Innoviva	$411.33M	3.84	$271.17M	$6.01	3.56

97.6% of Repligen shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 0.6% of Repligen shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Repligen has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Summary

Repligen beats Innoviva on 9 of the 17 factors compared between the two stocks.

How does Innoviva compare to Alkermes?

Innoviva (NASDAQ:INVA) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Innoviva presently has a consensus target price of $36.20, suggesting a potential upside of 69.00%. Alkermes has a consensus target price of $45.40, suggesting a potential upside of 7.61%. Given Innoviva's higher possible upside, analysts clearly believe Innoviva is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76

Innoviva has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

In the previous week, Alkermes had 1 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for Alkermes and 4 mentions for Innoviva. Alkermes' average media sentiment score of 1.29 beat Innoviva's score of 0.58 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Innoviva shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Innoviva has higher earnings, but lower revenue than Alkermes. Innoviva is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.84	$271.17M	$6.01	3.56
Alkermes	$1.48B	4.76	$241.66M	$0.90	46.88

Innoviva has a net margin of 119.89% compared to Alkermes' net margin of 9.78%. Innoviva's return on equity of 33.33% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Alkermes	9.78%	9.26%	5.66%

Summary

Alkermes beats Innoviva on 10 of the 17 factors compared between the two stocks.

How does Innoviva compare to Ligand Pharmaceuticals?

Innoviva (NASDAQ:INVA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Innoviva currently has a consensus price target of $36.20, indicating a potential upside of 69.00%. Ligand Pharmaceuticals has a consensus price target of $257.71, indicating a potential upside of 11.10%. Given Innoviva's higher possible upside, equities analysts clearly believe Innoviva is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Innoviva has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

Innoviva has higher revenue and earnings than Ligand Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.84	$271.17M	$6.01	3.56
Ligand Pharmaceuticals	$268.09M	17.34	$124.45M	$7.37	31.47

In the previous week, Ligand Pharmaceuticals had 4 more articles in the media than Innoviva. MarketBeat recorded 8 mentions for Ligand Pharmaceuticals and 4 mentions for Innoviva. Ligand Pharmaceuticals' average media sentiment score of 1.34 beat Innoviva's score of 0.58 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a net margin of 119.89% compared to Ligand Pharmaceuticals' net margin of 55.95%. Innoviva's return on equity of 33.33% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Ligand Pharmaceuticals beats Innoviva on 9 of the 16 factors compared between the two stocks.

How does Innoviva compare to Celldex Therapeutics?

Innoviva (NASDAQ:INVA) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, Innoviva had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 4 mentions for Innoviva and 2 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.31 beat Innoviva's score of 0.58 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva presently has a consensus price target of $36.20, suggesting a potential upside of 69.00%. Celldex Therapeutics has a consensus price target of $49.78, suggesting a potential upside of 58.38%. Given Innoviva's higher probable upside, analysts plainly believe Innoviva is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Innoviva has a net margin of 119.89% compared to Celldex Therapeutics' net margin of 0.00%. Innoviva's return on equity of 33.33% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Innoviva has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.84	$271.17M	$6.01	3.56
Celldex Therapeutics	$1.54M	1,601.91	-$258.76M	-$4.26	N/A

99.1% of Innoviva shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Innoviva has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Summary

Innoviva beats Celldex Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Innoviva compare to BioCryst Pharmaceuticals?

Innoviva (NASDAQ:INVA) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Innoviva and Innoviva both had 4 articles in the media. BioCryst Pharmaceuticals' average media sentiment score of 0.91 beat Innoviva's score of 0.58 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva presently has a consensus target price of $36.20, suggesting a potential upside of 69.00%. BioCryst Pharmaceuticals has a consensus target price of $20.70, suggesting a potential upside of 132.32%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Innoviva has a net margin of 119.89% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Innoviva's return on equity of 33.33% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Innoviva has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

Innoviva has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.84	$271.17M	$6.01	3.56
BioCryst Pharmaceuticals	$874.84M	2.59	$263.86M	-$1.78	N/A

Summary

BioCryst Pharmaceuticals beats Innoviva on 8 of the 15 factors compared between the two stocks.

Get Innoviva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INVA vs. The Competition

Export

Metric	Innoviva	Large Cap Pharma Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.58B	$307.51B	$6.41B	$12.57B
Dividend Yield	N/A	2.76%	2.68%	5.31%
P/E Ratio	3.56	27.39	21.61	26.27
Price / Sales	3.84	5.06	561.77	114.93
Price / Cash	4.26	13.10	27.44	37.60
Price / Book	1.36	7.85	10.04	6.86
Net Income	$271.17M	$11.61B	$3.56B	$337.26M
7 Day Performance	-4.63%	-1.32%	2.82%	3.58%
1 Month Performance	N/A	N/A	N/A	-0.79%
1 Year Performance	9.06%	22.60%	37.62%	39.67%

Innoviva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INVA Innoviva	3.5815 of 5 stars	$21.42 flat	$36.20 +69.0%	+9.1%	$1.58B	$411.33M	3.56	100
RGEN Repligen	3.899 of 5 stars	$115.06 +1.5%	$166.15 +44.4%	+5.3%	$6.49B	$738.26M	127.85	2,000
ALKS Alkermes	2.6204 of 5 stars	$36.80 -0.4%	$45.40 +23.4%	+36.8%	$6.13B	$1.48B	40.89	2,050	Positive News Gap Down
LGND Ligand Pharmaceuticals	3.4778 of 5 stars	$229.33 +3.2%	$257.71 +12.4%	+124.8%	$4.60B	$268.09M	31.12	80	Positive News Gap Down
CLDX Celldex Therapeutics	2.4287 of 5 stars	$30.73 +0.5%	$49.78 +62.0%	+61.3%	$2.41B	$865K	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INVA) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innoviva (INVA) Competitors

INVA vs. RGEN, ALKS, LGND, CLDX, and BCRX

How does Innoviva compare to Repligen?

Summary

How does Innoviva compare to Alkermes?

Summary

How does Innoviva compare to Ligand Pharmaceuticals?

Summary

How does Innoviva compare to Celldex Therapeutics?

Summary

How does Innoviva compare to BioCryst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innoviva (INVA) Competitors

INVA vs. RGEN, ALKS, LGND, CLDX, and BCRX

How does Innoviva compare to Repligen?

Do analysts rate RGEN or INVA?

Does the media refer more to RGEN or INVA?

Is RGEN or INVA more profitable?

Which has higher valuation & earnings, RGEN or INVA?

Do insiders and institutionals hold more shares of RGEN or INVA?

Which has more volatility and risk, RGEN or INVA?

Summary

How does Innoviva compare to Alkermes?

Do analysts rate INVA or ALKS?

Which has more risk and volatility, INVA or ALKS?

Does the media favor INVA or ALKS?

Do insiders and institutionals have more ownership in INVA or ALKS?

Which has higher valuation and earnings, INVA or ALKS?

Is INVA or ALKS more profitable?

Summary

How does Innoviva compare to Ligand Pharmaceuticals?

Do analysts prefer INVA or LGND?

Which has more volatility and risk, INVA or LGND?

Which has stronger valuation & earnings, INVA or LGND?

Does the media favor INVA or LGND?

Is INVA or LGND more profitable?

Do insiders and institutionals believe in INVA or LGND?

Summary

How does Innoviva compare to Celldex Therapeutics?

Does the media prefer INVA or CLDX?

Do analysts prefer INVA or CLDX?

Is INVA or CLDX more profitable?

Which has better valuation and earnings, INVA or CLDX?

Do institutionals and insiders hold more shares of INVA or CLDX?

Which has more risk and volatility, INVA or CLDX?

Summary

How does Innoviva compare to BioCryst Pharmaceuticals?

Do institutionals and insiders hold more shares of INVA or BCRX?

Does the media prefer INVA or BCRX?

Do analysts recommend INVA or BCRX?

Is INVA or BCRX more profitable?

Which has more volatility and risk, INVA or BCRX?

Which has higher valuation and earnings, INVA or BCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools